TY - JOUR
T1 - T-DM1 and brain metastases
AU - Fabi, Alessandra
AU - Alesini, Daniele
AU - Valle, Enrichetta
AU - Moscetti, Luca
AU - Caputo, Roberta
AU - Caruso, Michele
AU - Carbognin, Luisa
AU - Ciccarese, Mariangela
AU - La Verde, Nicla
AU - Arpino, Grazia
AU - Cannita, Katia
AU - Paris, Ida
AU - Santini, Daniele
AU - Montemurro, Filippo
AU - Russillo, Michelangelo
AU - Ferretti, Gianluigi
AU - Filippelli, Gianfranco
AU - Rossello, Rosalba
AU - Fabbri, Agnese
AU - Zambelli, Alberto
AU - Leonardi, Vita
AU - D'Ottavio, Anna Maria
AU - Nisticò, Cecilia
AU - Stani, Simonetta
AU - Giampaglia, Marianna
AU - Scandurra, Giusy
AU - Catania, Giovanna
AU - Malaguti, Paola
AU - Giannarelli, Diana
AU - Cognetti, Francesco
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: We reported the results of an Italian large retrospective analysis that evaluated the effectiveness and safety of T-DM1 in ‘field-practice’ breast cancer patients. We performed a sub-analysis to investigate the clinical activity of T-DM1 in patients with brain metastases (BMs). Methods: The records of 87 adult women with HER2-positive breast cancer and BMs treated with T-DM1 were reviewed. Their clinical outcomes were compared with those of 216 patients without central nervous system (CNS) involvement. Results: Response to T-DM1 treatment in BMs was available for 53 patients in the BM group (60.9%): two patients reported a complete response (3.8%), 11 patients obtained partial response (20.7%; overall response rate: 24.5%), 16 patients had a stable disease (30.1%). Regarding extracranial disease, a total of 77 and 191 patients were evaluable for response in BM group and non-BM group, respectively. The overall response rate was 35.1% in the BM group and 38.3% in the non-BM group; disease control rate was 53.3% and 66.6%, respectively. At a median follow-up of 16 months (range: 1–55), median cumulative progression-free survival (PFS) was 7 months (95% CI: 5.4–8.6) in the BM group and 8 months (95% CI: 5.7–10.3) in the non-BM group. In the second-line setting, PFS was 5 (95% CI: 3.1–6.9) versus 11 (95% CI: 7.1–14.9) months (p = 0.01). Overall survival was 14 months (95% CI: 12.2–15.8) in the BM group and 32 months (95% CI: 24.4–39.6) in the non-BM group (p <0.0001). Conclusions: T-DM1 is active in breast cancer patients with BMs.
AB - Background: We reported the results of an Italian large retrospective analysis that evaluated the effectiveness and safety of T-DM1 in ‘field-practice’ breast cancer patients. We performed a sub-analysis to investigate the clinical activity of T-DM1 in patients with brain metastases (BMs). Methods: The records of 87 adult women with HER2-positive breast cancer and BMs treated with T-DM1 were reviewed. Their clinical outcomes were compared with those of 216 patients without central nervous system (CNS) involvement. Results: Response to T-DM1 treatment in BMs was available for 53 patients in the BM group (60.9%): two patients reported a complete response (3.8%), 11 patients obtained partial response (20.7%; overall response rate: 24.5%), 16 patients had a stable disease (30.1%). Regarding extracranial disease, a total of 77 and 191 patients were evaluable for response in BM group and non-BM group, respectively. The overall response rate was 35.1% in the BM group and 38.3% in the non-BM group; disease control rate was 53.3% and 66.6%, respectively. At a median follow-up of 16 months (range: 1–55), median cumulative progression-free survival (PFS) was 7 months (95% CI: 5.4–8.6) in the BM group and 8 months (95% CI: 5.7–10.3) in the non-BM group. In the second-line setting, PFS was 5 (95% CI: 3.1–6.9) versus 11 (95% CI: 7.1–14.9) months (p = 0.01). Overall survival was 14 months (95% CI: 12.2–15.8) in the BM group and 32 months (95% CI: 24.4–39.6) in the non-BM group (p <0.0001). Conclusions: T-DM1 is active in breast cancer patients with BMs.
KW - Brain metastases
KW - Metastatic breast cancer
KW - T-DM1
KW - Trastuzumab-emtansine
U2 - 10.1016/j.breast.2018.07.004
DO - 10.1016/j.breast.2018.07.004
M3 - Articolo
VL - 41
SP - 137
EP - 143
JO - Breast
JF - Breast
SN - 0960-9776
ER -